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Summary
Morphine is an exceptionally effective analgesic whose
utility is compromised by the development of toler-
ance and dependence to the drug. Morphine analge-
sia and dependence are mediated by its activity at the
mu opioid peptide (MOP) receptor [1]. The MOP re-
ceptor is activated not only by morphine, but also by
other opiate drugs such as methadone and endoge-
nous opioids such as endorphins. Morphine, how-
ever, is a unique opioid agonist ligand because it fails
to induce endocytic trafficking of the MOP receptor
[2], whereas the endogenous ligands and methadone
do facilitate endocytosis [3]. Using the unique phar-
macology of the MOP receptor and its proposed exis-
tence as an oligomeric structure [4], we designed a
pharmacological cocktail that facilitates endocytosis
of the MOP receptor in response to morphine. This
cocktail consists of morphine and a small dose of
methadone. Importantly, this cocktail, while retaining
full analgesic potency, does not promote morphine
dependence. We further demonstrate that dependence
is reduced, at least in part, because endocytosis of
the MOP receptor in response to morphine prevents
the upregulation of N-methyl-D-aspartate (NMDA) re-
ceptors.
Results and Discussion
We found that a low dose of methadone facilitated the
ability of morphine to induce MOP-receptor endocyto-
sis both in HEK293 cells stably expressing an epitope-
tagged version of the MOP receptor (Figures 1A and
1B) and in rat brain (Figures 1D and 1E). We utilized
methadone, in particular the mixed dl-enantiomer of
this drug, for these studies because it is widely avail-
able and inexpensive to produce, and the mixed enanti-
omer is the drug principally used clinically [5]. As
shown previously [6], saturating doses of methadone
(1 M) promote endocytosis of the MOP receptor,
whereas saturating doses of morphine (1 M) do not
(Figure 1A). We propose, then, that methadone- and
morphine-occupied receptors are in different activated
conformations, whereby the methadone-activated con-
formation better engages the endocytic machinery. We
attribute the ability of a small number of dl-methadone-
activated receptors to facilitate endocytosis of the mor-
phine-activated receptors to the oligomeric nature of
the opioid receptors [7]. Specifically, we propose that*Correspondence: shooz2@itsa.ucsf.eduthe MOP receptors exist as dimers/oligomers and that
a single methadone-occupied receptor is sufficient to
promote endocytosis of the dimer/oligomer complex
when the other protomer(s) are occupied by morphine.
This effect was observed with a subendocytic dose of
dl-methadone in both the periaqueductal gray (PAG)
(Figure 1D), a region critical for the analgesic properties
of morphine [8], and the ventral tegmental area (VTA)
(Figure 1E), a region critical for the rewarding properties
of morphine [9].
Chronic morphine treatment of animals, as well as
cells in culture, produces a compensatory upregulation
of the cAMP pathway [10–12], a phenomenon termed
cAMP superactivation. These elevated cAMP levels
reflect cellular adaptive changes, which include in-
creased expression of certain types of adenylyl cy-
clase, protein kinase A (PKA), and cAMP response ele-
ment binding protein (CREB) (reviewed in [13, 14]). This
phenomenon has been observed both in vitro and in
brain regions implicated in addiction; these regions in-
clude the VTA [15], the locus coeruleus [11] and the
striatum [16]. Importantly, these elevated levels of
cAMP are responsible for changes in gene expression
as well as for alterations in neurotransmitter release
[14, 15, 17–19], making cAMP superactivation a hall-
mark of opiate tolerance and dependence.
Previously, we have demonstrated that receptor mu-
tations that promote endocytosis of the MOP receptor
in response to morphine can reduce this compensatory
cAMP upregulation [20]. We therefore examined whether
small doses of dl-methadone, which facilitated mor-
phine-induced endocytosis, would likewise alter cAMP
superactivation. As expected, morphine (1 M) induced
substantial cAMP superactivation (Figure 1C, gray bar,
p < .001 versus no treatment). dl-methadone (10 nM)
did not induce either receptor endocytosis (Figure 1A)
or significant cAMP superactivation at this low dose
(Figure 1C, striped bar). However, this low dose of dl-
methadone (10 nM) substantially reduced cAMP super-
activation in response to morphine (1 M) (Figure 1C,
black bar, p < .001 versus morphine alone), consistent
with its ability to promote MOP-receptor endocytosis
(Figures 1A and 1B).
We next examined whether a subendocytic dose of
dl-methadone (50 nmol), which facilitated morphine-
induced endocytosis in vivo (Figures 1D and 1E), could
affect the development of either morphine tolerance or
morphine dependence. First, rats were implanted with
a catheter intracerebroventricularly (i.c.v.) through which
drug or drug combinations were administered twice
daily. We chose a morphine dose (30 nmol) that gave
about 80% maximal possible effect (MPE) in the tail-
flick test to insure that both decreases and increases
in analgesia could be detected.
Rats treated with morphine alone developed pro-
found tolerance by day 5 (Figure 2A, red line, open cir-
cle, p < .001 day 1 versus day 5). dl-methadone alone
(50 nmol, black line, closed circle) produced no analge-
sia at this dose, nor did dl-methadone enhance acute
morphine analgesia on day 1 (Figure 2A, compare red
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(A) Biotin protection assay to quantify endocytosis. HEK293 cells stably expressing FLAG-tagged MOP receptors were biotinylated with thio-
clavable biotin and treated with agonist/agonist combinations at stated concentrations or left untreated. Cells were stripped of remaining
cell-surface biotin with membrane impermeant reducing agent, and “protected” receptors were immunoprecipitated and visualized (see the
Supplemental Experimental Procedures in the Supplemental Data available with this article online). Methadone enhanced morphine-induced
endocytosis. Saturating concentrations of morphine alone (1 M) or d-methadone (1 M) as well as low concentrations of dl-methadone (100
nM, 10 nM) failed to promote endocytosis. A saturating concentration (1 M) of dl-methadone alone promotes endocytosis.
(B) Immunocytochemical staining. HEK293 cells stably expressing FLAG-tagged MOP receptors were fed antibody to the epitope tag and
exposed to saturating concentrations of morphine (1 M), 10 nM methadone, or both 1 M morphine and 10 nM methadone, and then fixed
and stained for receptor. Methadone enhanced morphine-induced MOP-receptor endocytosis.
(C) cAMP superactivation. CRE-luciferase expression was assessed in HEK293 cells stably expressing both the MOP receptor and a CRE-
luciferase reporter gene [20]. Cells were treated with drug or drug combinations as listed for 14 hr and washed thoroughly, then treated with
2 M forskolin for 4 hr. Morphine induced cAMP superactivation, whereas methadone decreased morphine-induced cAMP superactivation
(*** p < .001 NT versus MS; ### p < .001 MS versus MS + MD, 1× ANOVA, Tukey post-test). The following abbreviations were used: MD, dl-
methadone; MS, morphine sulfate; and NT, no treatment.
(D and E) Immunohistochemistry in rat brain. MOP-receptor distribution in PAG (D) and VTA (E) neurons of rats was assessed 30 min after
acute i.c.v. administration of opiate drug or drug combinations. dl-methadone at 50 nmol or an analgesic dose of morphine (30 nmol) alone
did not promote endocytosis of the MOP receptor, whereas coadministration of both drugs induced MOP-receptor endocytosis in neurons
from both PAG and VTA. PAG denotes periaqueductal gray, and VTA denotes ventral tegmental area. For quantification, slides were encoded
and vesicles counted by a second party from at least 10 cells from 2 rats per condition (*** p < .001: MS 30 nmol + MD 50 nmol versus MS
30 nmol or MD 50 nmol).line, open circle and green line, open triangle). However,
dl-methadone prevented the development of morphine
tolerance at both the 50 nmol (Figure 2A, green line,
open triangle) and also a lower 20 nmol dose (Figure
2A, blue line, closed square). A dl-methadone dose (5
nmol) that did not promote morphine-induced endocy-
tosis of the MOP receptor in the rat brain (Figure 3)
did not affect the development of morphine tolerance
(Figure 2A, purple line, open square).
We have previously shown that enhanced endocyto-
sis of the MOP receptor in response to morphine can
reduce analgesic tolerance. However, the role of endo-
cytosis in the development of morphine dependence
has not been examined. Physical dependence on mor-
phine is often associated with the development of toler-
ance, suggesting that these behavioral side effects of
prolonged morphine use may be connected. However,
these phenomena are not always observed together.
For example, β-arrestin-2 knockout mice show reduced
morphine tolerance but nevertheless develop morphine
dependence [16]. We therefore assessed whether our
opiate cocktail that reduced tolerance could also re-
duce morphine dependence. Indeed, dl-methadone,
when coadministered with morphine, did reduce the
development of morphine dependence, as measuredby a significant decrease in the global score for nalox-
one-precipitated withdrawal signs (Figure 2B, p < .01
versus morphine alone). This effect was selective to
methadone doses that facilitated morphine-induced
endocytosis because very low doses of dl-methadone
(5 nmol, Figure 2B, purple bar) had no effect on reduc-
ing the withdrawal signs.
To ensure that reduced tolerance and dependence
were associated with enhanced endocytosis of the
MOP receptor, we assessed the distribution of the MOP
receptors in the brains of the rats that had been treated
with drug or drug combinations for 5 days from experi-
ment 2A. Morphine failed to induce MOP-receptor en-
docytosis even after 5 days of treatment (Figures 3A
and 3B, left panels). Likewise, the 50 nmol dose of dl-
methadone alone did not promote substantial endocy-
tosis (Figures 3A and 3B). In contrast, MOP receptors
in rats treated with the opiate cocktail of morphine 30
nmol + methadone 50 nmol were distributed not only
on the plasma membrane, but also within intracellular
compartments (Figures 3A and 3B, p > .001 versus mor-
phine alone). The 5 nmol dose of methadone in combi-
nation with morphine did not promote endocytosis (Fig-
ures 3A and 3B, right panels), consistent with the
inability of this dose to prevent tolerance and depen-
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on Morphine and the Morphine-Methadone
Cocktail
(A and C) Analgesic tolerance. (A) Rats were
implanted with an i.c.v. cannula, and mor-
phine tolerance development was measured
with a tail-flick assay over a 5 day period.
Rats treated with an analgesic dose of mor-
phine (30 nmol) developed substantial toler-
ance by day 5, whereas rats receiving the
same dose of morphine plus varying doses
of dl-methadone showed no tolerance at all
but the lowest dose of methadone (*** p <
0.001: MS 30 nmol alone [red line, open cir-
cles] versus MS 30 nmol + MD 50 nmol
[green line, open triangles] or MS 30 nmol +
MD 20 nmol [blue line, closed squares];
### p < 0.001: MS 30 nmol on day 5 versus
day 1; MD 50 nmol alone [black line, closed
circles]; MS 30 nmol + MD 5 nmol [purple
line, open squares]). (C) Rats were implanted
with an i.c.v. cannula, and morphine toler-
ance development was measured as above.
Rats treated with morphine alone or
morphine plus d-methadone (MS 30 nmol + d-MD 50 nmol [light-green line, open squares]) developed substantial tolerance (*** p < 0.001:
day 5 versus day 1 MS 30 nmol + d-MD 50 nmol). d-methadone alone did not produce analgesia (gray line, closed circles). MPE denotes
maximal possible effect (see Supplemental Experimental Procedures).
(B and D) Physical dependence. Rats from the tolerance experiments were injected with naloxone (3 mg/kg) subcutaneously (s.c.) after the
final tail-flick assay on day 5, and withdrawal signs were monitored. (B) Withdrawal was significantly attenuated with several doses of dl-
methadone compared with morphine alone (*** p < 0.001: MD 50 nmol versus MS 30 nmol; ** p < 0.01: MS 30 nmol + dl-MD 50 nmol versus
MS 30 nmol; NS, no significance versus MS 30 nmol) (D) Withdrawal was not significantly attenuated by d-methadone (*** p < 0.001: d-MD
50 nmol versus MS 30 nmol; NS, no significance versus MS 30 nmol). For detailed statistics, please see Supplemental Experimental Pro-
cedures. The following abbreviations were used: MS, morphine sulfate; dl-MD, dl-methadone; and d-MD, d-methadone.of whether NMDA antagonism by d-methadone con-enantiomer primarily responsible for analgesia [24] and
Figure 3. Immunohistochemical Staining of MOP Receptors in PAG and VTA Neurons of Rats from Figure 2A
MOP receptors (green) were primarily localized to the plasma membrane of neurons of rats treated with morphine at 30 nmol, dl-methadone
at 50 nmol, and morphine 30 nmol + dl-methadone 5 nmol. Pronounced MOP-receptor endocytosis was found after coadministration of
morphine 30 nmol + dl-methadone 50 nmol. For quantification, slides were encoded and vesicles counted by a second party from at least 10
cells from 2 rats per condition (*** p < .001 MS 30 nmol + MD 50 nmol versus MS 30 nmol, dl-methadone at 50 nmol, and morphine 30 nmol
+ dl-methadone 5 nmol). Red is NeuN in PAG and TH in VTA. Note that the MOP-receptor-positive cells are nondopaminergic neurons. The
following abbreviations were used: PAG, periaqueductal gray; VTA, ventral tegmental area; TH, tyrosine hydroxylase; MS, morphine sulfate;
dl-MD, dl-methadone; and d-MD, d-methadone.dence (Figures 2A and 2B). Together, these data h
dstrongly indicate a correlation between MOP-receptor
trafficking and behavioral tolerance and dependence. p
tMethadone is a unique opioid drug in that it pos-
sesses not only MOP-receptor agonist activity but also a
[antagonist activity at NMDA receptors [21]. This fact
is highly relevant to this study because there is much u
pevidence that the NMDA receptor system is involved in
the manifestation of morphine tolerance and depen- t
sdence (for review, see [22, 23]). Methadone is a mixed
enantiomer of d- and l-methadone. l-methadone is the aas a high affinity for the MOP receptor [25]. d-metha-
one has a low affinity for the MOP receptor [25], is a
oor analgesic [26], and does not promote MOP-recep-
or endocytosis (Figure 1A). However, previously, d-meth-
done has been shown to prevent morphine tolerance
27], and this effect of d-methadone has been attrib-
ted specifically to the NMDA receptor antagonist
roperties of this enantiomer (kd w5–7 M [28]). Al-
hough the methadone doses used in our studies were
ubstantially lower than those reported to block toler-
nce, these observations raise the reasonable question
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(A–C) Protein levels were assessed in different rat brain regions by immunoblot. Data are expressed as mean ± SEM. Tissue samples were
analyzed from two rats in each group, and at least two separate experiments were conducted for each rat. The following abbreviations were
used: FC, frontal cortex; Str, striatum; NAc, nucleus accumbens; Thal, thalamus; Amyg, amygdala; and PAG, periaqueductal gray. ** p < 0.01,
compared with saline group; # p < 0.05, compared with morphine plus dl-methadone group.tributed to the anti-tolerance and/or -dependence ef-
fects of the morphine-methadone cocktail because the
methadone utilized for our studies contains both the d-
and l-enantiomers.
To examine this possibility, we utilized a morphine/
d-methadone cocktail, which should retain any NMDA
antagonism properties of our morphine/dl-methadone
cocktail but not enhance MOP-receptor endocytosis.
As expected, d-methadone (50 nmol) showed no anal-
gesia (Figure 2C, gray line, closed circle), nor did it en-
hance acute morphine analgesia on day 1 (Figure 2C,
green line, open square). Furthermore, at the dose ad-
ministered in this study, d-methadone did not prevent
morphine tolerance (Figure 2C, green line, open square)
or dependence (Figure 2D). This strongly suggests that
significant NMDA antagonism is not occurring at this
methadone dose and that NMDA antagonism is not re-
sponsible for the ability of the mixed dl-methadone in
our cocktail to prevent morphine tolerance and depen-
dence. Although NMDA antagonists have been shown
to block morphine tolerance and dependence (see be-
low), taken together, our data suggest that it is the en-
hanced endocytosis of the MOP receptor, not NMDA
antagonism, that is preventing morphine tolerance and
dependence during administration of the cocktail.
We propose that endocytosis of the MOP receptor in
response to morphine is reducing tolerance and depen-
dence, at least in part, by reducing superactivation of
the cAMP pathway (Figure 1; see [20]). However, there
are several additional biochemical markers that havebeen found to be associated with morphine tolerance
other than cAMP superactivation. These include redis-
tribution of delta opioid receptors from intracellular
compartments, where they normally reside, to the cell
surface [29, 30] and upregulation of systems such as
cholecystokinin and orphanin FQ/nociceptin (for re-
view, see [31]).
One of the most intensely studied markers of mor-
phine tolerance and dependence is the alteration of
NMDA receptor number and function. Specifically, both
the NR2A [32] and the NR1 [33] subunits of the NMDA
receptor have been found to be upregulated after
chronic morphine treatment. The fact that this NMDA
receptor upregulation can be blocked by NMDA antag-
onists (for review, see [22]) could explain why NMDA
antagonists, such as MK801 (kd w2 nM [21]) and
d-methadone at high doses (kd w5–7 M [28]), inhibit
the development of morphine tolerance [33–35] and de-
pendence [34]. Because activity at the MOP receptor
has been shown to affect NMDA receptor function [36,
37], we investigated whether facilitating endocytosis of
the MOP receptor influences morphine tolerance and
dependence by altering the upregulation of the NMDA
receptor.
First, we examined whether NR1 or NR2A were
upregulated after the chronic morphine treatment uti-
lized for our behavioral experiments. Expression of NR1
and NR2A (Figures 4A and 4B) was assessed in several
brain regions after the behavioral experiments in Figure
2A. There was a trend toward upregulation of both NR1
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phine. However, the only statistically significant change
was observed with the NR2A subunit in the striatum
(Figure 4B), where expression was consistently in-
creased by 50%. This observation is intriguing because
the striatum is a brain region that shows significant
cAMP superactivation in response to chronic morphine
[16], suggesting these two phenomena may be related.
In addition, previous studies have indicated that the
striatum is more sensitive to changes in gene expres-
sion as a consequence of chronic morphine treatment
than other anatomically closely related brain regions
such as the nucleus accumbens [38], which might ex-
plain why we find the greatest changes in this region.
We next examined whether coadministration of dl-
methadone (50 nmol), which facilitated endocytosis of
the MOP receptor (Figures 1C and 1D) and prevented
tolerance and dependence (Figures 2A and 2B), af-
fected the upregulation of NR2A. Indeed, rats treated
with morphine together with dl-methadone (50 nmol)
did not show upregulation of NR2A (Figure 4C, com-
pare lanes 1 and 3), suggesting dl-methadone pre-
vented morphine-induced upregulation of NR2A. Im-
portantly, coadministration of morphine together with
d-methadone (50 nmol) did not prevent NR2A upregula-
tion (Figure 4C, lane 4), consistent with the inability of
d-methadone to prevent morphine tolerance and de-
1pendence (Figures 2C and 2D).
Together, these results suggest that small, subendo-
cytic doses of methadone, when combined with mor- 1
phine, facilitate endocytosis and thereby prevent cellu-
lar adaptive changes, including cAMP superactivation
and NR2A upregulation, associated with chronic mor-
1phine use. These adaptive changes, in turn, likely com-
bine to manifest in behavioral tolerance and depen-
dence. Therefore, we propose that an opiate cocktail
that combines morphine with a small dose of metha- 1
done would increase the effectiveness of morphine for
the treatment of chronic pain. In addition, our results
1suggest that patients requiring prolonged opioid treat-
ment would have a reduced liability for opioid depen-
1
dence when treated with a cocktail of morphine and
methadone.
1
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